Abstract: A method of treating or preventing neurological injury in a subject who has suffered a stroke is described. The method includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject. Methods for prophylaxis against neurological injury from stroke, and methods for treating or preventing cardiovascular disease by administration of a therapeutically effective amount of cerium oxide nanoparticles are also described.

Abstract: Disclosed are water-based cosmetic compositions comprising a synthetic non-associative thickening polymer, a synthetic associative thickening polymer, an emulsifier, a film forming polymer, and a liquid fatty substance. The ratio of the synthetic non-associative thickening polymer to the synthetic associative thickening polymer is greater than 1:1, or alternatively, said ratio is less than or equal to 1:1.

Abstract: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.

Abstract: A new composition for repelling pests is disclosed, wherein said composition comprises an extract produced from at least one plant chosen from the group consisting of Achillea spp., Varthemia iphionoides, Haplophyllum turberculatum, Pulicaria incisa, Asteriscus graveolens, Tanacetum sinaicum, Verbascum spp., Artemisia spp., and Ammi visnaga. In preferred embodiments, the extract is produced from Achillea spp. Methods for applying the composition are also disclosed. The composition has been shown to be effective against a variety of pests, including aphids, thrips, tomato borers, tomato leaf miners, and whiteflies.

Abstract: A vacuum processing apparatus is configured to include a process chamber, a turntable provided in the process chamber, and a substrate receiving area provided in one surface of the turntable and including a regulation part formed therearound to regulate a position of a substrate. A transfer mechanism is provided outside the process chamber, and a lifting member is configured to support the substrate and to move up and down in order to transfer the substrate between the transfer mechanism and the turntable. An exhaust mechanism is configured to selectively evacuate a gap between the substrate receiving area and the substrate before the lifting member places the substrate on the substrate receiving area.

Abstract: [Problem] A microbial pesticidal composition containing viable spores of a bacterium belonging to the genus Bacillus and a chemical pesticide, in which the spores can be preserved stably in a living state for a long period of time, and a method for preserving the spores stably in a living state for a long period of time, are provided. [Dissolution Means] Viable spores of Bacillus subtilis and/or Bacillus amyloliquefaciens are blended with at least one member selected from a metal oxide, a metal hydroxide, a metal oxide silicic acid salt, and a metal hydroxide silicic acid salt.

Abstract: Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil.

Abstract: A cosmetic composition is described that includes particles of a polymeric composition that includes a polymer matrix and one or a plurality of mineral filler(s), uniformly dispersed in the polymer matrix, having properties of absorption and/or emission in the far infrared region ranging from 2 ?m to 20 ?m. The particles of the polymeric composition can be dispersed in a carrier fluid including water and/or one or a plurality of organic fluids. The composition is, for example, intended to prevent or reduce the signs of skin aging.

Abstract: The present invention describes a medical device comprising a set of particles of titanium oxide, wherein at least a substantial amount of the particles are of micrometer—millimeter size, and wherein at least 10 wt % of the titanium oxide is in the amorphous form.

Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.

Abstract: The invention relates to the treatment of different bone injuries, particularly fractures and fissure fractures, and can be used in medical and veterinary therapy and surgery. In order to reduce the time taken for bone tissue to regenerate at the site of damage or a defect and to reduce the time taken for the normal physiological functioning of an injured bone o be restored, a method is used for regenerating bone tissue by fixing fragments of the damaged bone with a plaster cast or a bandage made of a polymer material and introducing into the fracture zone an aqueous solution containing 1-hydroxyethylidene diphosphonic acid in an amount of (1.80-2.06) g/l, anhydrous calcium chloride in an amount of (1.44-2.22) g/l, gadolinium (III) nitrate hexahydrate in an amount of (0.3-0.40) g/l and dysprosium (III) chloride hexahydrate in an amount of (0.038-0.076) g/l, with a pH of (7.3-7.8), wherein, prior to being introduced into the fracture zone, the above solution is brought to a temperature of (30-100)° C.

Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury.

Abstract: Methods of using a polymeric composition are described for preventing or reducing the signs of aging. The polymeric composition can include a polymer matrix and one or a plurality of mineral filler(s), uniformly dispersed in the polymer matrix, having properties of absorption and/or emission in the far infrared region ranging from 2 ?m to 20 ?m.

Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

Abstract: This invention provides cosmetics containing a multi-functional composite powder having the properties of (a) an excellent adhesiveness, (b) an excellent extendability, (c) an appropriate glossy effect, (d) a homogeneous cosmetic film, (e) an appropriate covering capability, (f) a cosmetic film not causing a white masking, (g) a high compatibility between a color appearance of cosmetics and a color tone of the cosmetic film, (h) an excellent soft-focusing capability, (i) an excellent ultraviolet protective effect, and the like. The multi-functional composite powder is constituted by a scale-like base material, a group of particles comprising at least fine particles of titanium dioxide deposited on a surface of the scale-like base material, and a thin film of a composite oxide containing titanium and iron coated thereon.

Abstract: An antibacterial paper comprises a paper substrate, wherein at least one external surface of the paper substrate is coated with an antibacterial coating layer containing titanium dioxide particles uniformly distributed therein, the average particle size of the titanium dioxide particles is less than or equal to 200 nanometers (nm), and the mass percentage of the titanium dioxide particles contained in the antibacterial coating layer is more than or equal to 5% of the mass of the antibacterial coating layer.

Abstract: A sunscreen composition for application for plants comprises Titanium Dioxide (TiO2), Zinc Oxide (ZnO), Silicon Dioxide (SiO2), a surfactant, wetting agent, dispersant (SWD) and water. The composition forms a suspension concentrate when combined that when diluted in water provides a solution that provides uniform coverage using convention spraying equipment. A method of protecting plants including turfgrass from ultraviolet radiation, heat stress and/or sunburn comprises combining TiO2, ZnO, SiO2, SWD and water to form a suspension concentrate. The suspension concentrate is then diluted in water and applied to an area in which sun protection is desired.

Abstract: The present invention relates to ceria nanocomposite, pharmaceutical composition comprising the ceria nanocomposite, and method for preparing same. More particularly, the present invention is directed to a ceria nanocomposite comprising a ceria nanoparticle, wherein the ceria nanoparticle is encapsulated with a surfactant and the surfactant is encapsulated with polyethylene glycol-phospholipid, pharmaceutical composition for preventing or treating ischemic stroke comprising thereof and method for preparing the same.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling.

Abstract: The invention relates to novel cyclic compounds (cyclic peptides), linkers useful as beta-turn promoters in cyclic peptides, and methods for treatment of malignant cells in vitro or in vivo using one or more linear and cyclic peptides. The peptides can act as integrin interaction inhibitors and may be used in the treatment of cancers as monotherapies or in combination with other anti-cancer agents, such as proteasome inhibitors, inhibitors of autophagy, alkylating agents, MEK inhibitors, FAK/PYK2 inhibitors, and EGFR inhibitors. The invention further concerns a method of predicting the binding of a cyclic or linear HYD1 peptide to a cancer cell by assessing overexpression of biomarkers such as CD44, VLA-4 integrin, basigin, CD138 (syndecan 1), NCAM, ICAM1, ICAM3, and CD59.

Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.

Abstract: The present invention provides a titanium dioxide dispersion having a good dispersibility and also provides a cosmetic containing the same. The titanium dioxide dispersion comprises (a) a hydrophobized, treated titanium dioxide powder; (b) one or more oils selected from isohexadecane, isododecane, 2-ethylhexyl 2-ethylhexanoate, isononyl isononate, 2-ethylhexyl isononanoate, isononyl 2-ethylhexanoate, and polypropylene glycol dipivalate; and (c) a siloxane compound represented by the following formula (1), preferably polyoxyalkylene/alkyl comodified organopolysiloxane.

Abstract: Methods of mitigating the effects of radiation exposure or providing a radioprotective effect in a subject are provided herein. The methods include administering a therapeutically effective amount of cerium oxide nanoparticles to the subject to mitigate the effects of radiation exposure or to offer a radioprotective effect to the subject. The cerium oxide nanoparticles are suitably less than 20 nm in diameter and have over 50% of the cerium in the 3+ oxidation state.

Abstract: The present invention relates to nanoparticle aggregates comprising osteopontin (OPN) and one or more particles containing calcium and/or strontium and to their use for reducing or preventing biofilm growth or for removing biofilm. The invention furthermore relates to the use of the nanoparticle aggregates for treating, alleviating or preventing biofilm-related diseases.

Abstract: Methods of using cerium oxide nanoparticles to promote angiogenesis are described. In a particular embodiment, a method of promoting angiogenesis in animal tissue comprises contacting the tissue with a composition comprising cerium oxide nanoparticles effective for stimulating proliferation of endothelial cells associated with the tissue.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

Abstract: The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

Abstract: A method of treating or preventing Helicobacter pylori infection in a subject includes the step(s) of: administering to the subject a composition. The composition has a carbonaceous material and an active particle. The active particle is coated on the carbonaceous material and made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.

Abstract: The present invention refers to a composite material including at least one upconversion particulate material that under near infrared (NIR) irradiation emits visible light of a wavelength between 380 and 740 nm, and at least one semiconductor particulate material that can absorb the visible light emitted by the at least one upconversion particulate material and upon absorbance generates reactive species, wherein the at least one upconversion particulate material and the at least one semiconductor particulate material are physiologically acceptable. The upconversion particulate material can comprises NaYF4 doped with a one rare earth metal. The bright fluorescence emitted from rare earth-doped NaYF4 upconversion particles is in the visible region of the electromagnetic spectrum and may be absorbed by a biocompatible photocatalysts such as TiO2 to produce reactive species. This allows the composite to be used for in vivo applications.

Abstract: The present invention relates to a water-in-oil emulsified skin cosmetic comprising the following ingredients (a) through (e): (a) Water: 5-50 wt % (b) Ethanol: 1-20 wt % (c) Volatile oil component: 2-50 wt % (d) Carboxy decyl trisiloxane represented by the following formula (1): 0.1-5 wt % (e) One, two or more selected from a group consisting of hydrophobized titanium dioxide, hydrophobized zinc oxide, and hydrophobized iron oxide: 2-50 wt %. The object of the present invention is to provide a water-in-oil emulsified skin cosmetic containing the aforementioned powder (e) wherein powdery squeakiness over time after application on the skin is suppressed and at the same time absorption into the skin at the time of application and the absence of stickiness after application on the skin are improved.

Abstract: The Invention relates to a particulate system for use in diminishing cell growth, in particular the growth of cancer cells, comprising one or more water soluble lanthanide compounds that are embedded in a solid biodegradable polymer particle, the polymer being selected from the group consisting of polycarbonic acids, polylactic acids, polyglycolic acids, polypeptides or combinations thereof.

Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Abstract: A method for producing triblock copolymer-coated metallic nanoparticle seeds which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticle seeds. A quantity of triblock copolymer-coated metallic nanoparticle seeds. A method for producing triblock copolymer-coated metallic nanoparticles which increases the size and shape homo-geneity of the triblock copolymer-coated metallic nanoparticles. A quantity of triblock copolymer-coated metallic nanoparticles. A method for producing modified metallic nanoparticles which increases the size and shape homogeneity of the modified metallic nanoparticles. A quantity of modified metallic nanoparticles.

Abstract: Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye.

Abstract: There is provided provide a method for efficiently producing a rutile type titanium sol having a particle diameter based on dynamic light scattering method of 5 nm to 100 nm that is excellent in dispersibility. The method for producing a rutile type titanium oxide sol comprising: process (a): mixing metastannic acid, a titanium alkoxide, a quaternary ammonium hydroxide, oxalic acid, and water so as to contain 0.02 moles to 0.8 moles of tin atoms, 0.1 moles to 3.5 moles of the quaternary ammonium hydroxide, and 0.1 moles to 8.0 moles of the oxalic acid with respect to 1 mole of titanium atoms of the titanium alkoxide to prepare a titanium-containing aqueous solution with a concentration in terms of TiO2 of 0.1% by mass to 15% by mass; and process (b): subjecting the titanium-containing aqueous solution obtained in process (a) to a hydrothermal treatment at a temperature from 100° C. to 170° C.

Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Abstract: A process for making cerium-containing nanoparticles with biocompatible stabilizers is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid, a stabilizer (chelator) selected from the group consisting of nitrilotriacetic acid, ethylene glycol tetraacetic acid and diethylenetriaminepentaacetic acid, and an oxidant, is provided, followed by a heating step to effectively form the nanoparticles. These biocompatible nanoparticles can be used to treat oxidative stress related diseases and events, such as ischemic stroke.

Abstract: The present invention relates to a heat-generating composition, comprising a hetero-structure nanomaterial which comprises (a) a first material comprising at least one component selected from the group consisting of a metal, a metal chalcogen, a metal pnicogen, an alloy and a multi-component hybrid structure thereof; and (b) a second material comprising at least one component selected from the group consisting of metal, metal chalcogen, metal pnicogen, alloy and the multi-component hybrid structure thereof; wherein the first material is enclosed in the second material; wherein at least one of the first material and the second material comprise a magnetic material. The specific loss power of the present nanomaterial is much higher than that of conventional nanomaterials (e.g., 40-fold higher than commercially accessible Feridex) and may be controlled by changing compositions or ratios of the first material and/or the second material.

Abstract: The Cu- and Ti-containing composition of the present invention contains titanium oxide having a rutile-type titanium oxide content of 15 mol % or more, and at least one divalent copper compound represented by the following formula (1). The Cu- and Ti-containing composition production method of the present invention is characterized by including stirring a mixture containing titanium oxide having a rutile-type titanium oxide content of 15 mol % or more, a divalent copper compound raw material represented by formula (2), water, and an alkaline compound, to thereby cause precipitation. The composition of the present invention exhibits excellent anti-viral property under light and in the dark, and excellent organic compound decomposition activity under light.

Abstract: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.

Abstract: Silver-containing particles, and methods of making silver-containing particles are disclosed.

Abstract: A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-? inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum.

Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.

Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.

Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Abstract: A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition.

Abstract: A garment treated with an antimicrobial agent that causes the garment to repel foreign objects when exposed to sunlight.

Abstract: A pharmaceutical composition or combination drug, which contains, as active ingredients, (a) a coordination compound composed of a block copolymer represented by the following formula I or formula II and cisplatin, and (b) gemcitabine hydrochloride. In the formulae I and II, R1, A, R2, R3, m and n are as defined in the description.